Iovance Biotherapeutics Inc. (2LB)
FSX
Real-time Data
06:00 AM
Day's Range
12.4452 wk Range
1.59Overview - 2LB - Iovance Biotherapeutics Inc.
Key Statistics
Valuation
Enterprise Value
4.78B
P/E (Trailing)
‪-11.39‬
P/E (Forward)
‪-5.52‬
PEG Ratio
‪0.17‬
Price / Sales (TTM)
‪17.31‬
Price / Book
‪8.76‬
EV / EBITDA
‪-20.70‬
Profitability
Gross Margin
‪56.10%‬
Profit Margin
‪-89.09%‬
Operating Margin
‪-52.26%‬
Return on Assets
‪-20.30%‬
Return on Equity
‪-40.36%‬
Ownership
Shares Outstanding
452.97M
Float
394.31M
Held by Insiders
‪0.35%‬
Held by Institutions
‪70.66%‬
Price stats
Beta
‪0.83‬
50-Day Avg
‪7.02‬
200-Day Avg
‪4.05‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 2LB - Iovance Biotherapeutics Inc.
Peers - 2LB - Iovance Biotherapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 2LBFSXIovance Biotherapeutics Inc.5.62BMarket Cap+83.67%52-week change-11.39P/E (Trailing)‪-89.09%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 2LB - Iovance Biotherapeutics Inc.
About
Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell therapy used in advanced melanoma, and Proleukin, which supports the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
